Though the FDA has requested no new data, the additional information reflects a major amendment to Rhythm’s supplemental new ...

Approval of J&J's Darzalex marks a milestone for high-risk sMM patients, but GlobalData analyst Biswajit Podder believes ...

Abzena and Mabqi have announced a partnership integrating antibody discovery capabilities with development and manufacturing ...

Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the MHRA for all four formulations of ...

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

The US Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat genetic ...

Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Cencora is set to invest $1bn by 2030 to expand its US pharmaceutical distribution network, adding resilience and capacity.

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Agentic AI was a point of emphasis on the first day of the 2025 Veeva Commercial summit held in Madrid, Spain.

The guidance change marks the latest adjustment Novo has made to its 2025 outlook as the company battles a changing market.